SIGA Technologies, Inc.

NASDAQ•SIGA

CEO: Dr. Dennis E. Hruby Ph.D.

セクター: Healthcare

業種: Drug Manufacturers - Specialty & Generic

上場日: 1997-09-10

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

連絡先情報

31 East 62nd Street, New York, NY, 10065, United States

212-672-9100

www.siga.com

時価総額

$341.03M

PER (TTM)

14.6

15.4

配当利回り

25.2%

52週高値

$9.62

52週安値

$4.29

52週レンジ

順位30Top 19.5%

5.1

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

堅調 • 5.1 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$3.80M+0.00%

直近4四半期の推移

EPS

-$0.08+0.00%

直近4四半期の推移

フリーCF

-$11.30M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Net Income Decreased Sharply Net income for 2025 was $23.28M, a substantial decrease from $59.21M reported in the prior year period.

Total Revenues Fell Significantly Total revenues for 2025 totaled $94.57M, reflecting a significant contraction from $138.72M recorded in 2024.

Cash Position Remains Robust Cash and cash equivalents held steady at $155.0M at December 31, 2025, supporting liquidity needs for the near term.

BARDA Contract Execution Cumulative oral TPOXX® delivery value under the 19C BARDA Contract reached $450.2M as of December 31, 2025.

リスク要因

Dependence on Government Contracts Substantial future revenue relies on U.S. Government commitment; failure to secure new contracts materially harms operations.

International Sales Dropped International sales sharply declined to $5.82M in 2025 from $23.0M in 2024, limiting diversification efforts.

EMA Mpox Authorization Review EMA CHMP referral on mpox effectiveness may recommend withdrawal, negatively impacting anticipated revenue streams.

Fixed Price Contract Exposure Fixed-price government contracts require absorbing cost overruns, potentially reducing profitability or causing material losses.

見通し

Smallpox PEP Submission Targeted Targeting Supplemental NDA submission for oral TPOXX® smallpox PEP indication within the next twelve months based on trial results.

IV TPOXX Manufacturing Transition Actively transferring IV TPOXX® manufacturing process from Patheon to a new third-party site, requiring FDA approval.

Expanding International Sales Efforts Reacquired international promotional rights; building out internal sales organization to pursue recurring non-U.S. government sales.

同業比較

売上高 (TTM)

OFIX

$822.31M

+2.9%

EBS

$742.90M

-28.8%

SNDL

$677.36M

+2.8%

粗利益率 (最新四半期)

RIGL

91.5%

+7.7pp

KALV

90.4%

+0.0pp

ESPR

83.5%

-30.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
OLMA	$1.47B	-9.5	-42.9%	0.2%
KALV	$1.05B	-6.2	-444.4%	84.7%
VTYX	$1.00B	-9.4	-48.1%	4.7%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-18.6%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

50%

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月30日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし